HCAT: Q2 2026 beat guidance, divestiture enabled debt repayment, and 2026 outlook reflects transformationQuartr·7 hours agoHCAT-335.00%
Health Catalyst shares are trading lower after the company issued Q3 sales and FY2026 sales guidance below estimates.benzinga_article·8 hours agoHCAT-335.00%
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga_article·8 hours agoHCAT-335.00%QDEL-672.00%
Health Catalyst Q2 FY26 net loss narrows 1% to $40.54 million; revenue falls 13% to $70.49 millionPUBT·9 hours agoHCAT-335.00%
16:03 ETHealth Catalyst Completes Sale of Vitalware, Sharpening Its Focus as a Healthcare Intelligence Companyprnewswire·9 hours agoHCAT-335.00%
Health Catalyst (HCAT) Q2 Earnings Report Preview: What To Look ForStock Story·2 days ago, 10:35 PMHCAT-335.00%STRF-50.00%
Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026 | HCAT Stock NewsStockTitan·Jul 28 at 08:30 AMHCAT-335.00%
Health Catalyst shareholders rejected charter restatement to phase out classified board structurePUBT·Jul 20 at 05:03 AMHCAT-335.00%
Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of "Hold" from BrokeragesMarket Beat·Jul 18 at 01:14 AMHCAT-335.00%
Health Catalyst Investors Approve Directors, Pay; Board Declassification FailsMarket Beat·Jul 16 at 05:03 PMHCAT-335.00%
